Trial reportAntimicrobial agents and chemotherapy2009
OPT-80 eliminates Clostridium difficile and is sparing of bacteroides species during treatment of C. difficile infection.
Trial report in Antimicrobial agents and chemotherapy, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 83 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
83 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Fidaxomicin versus vancomycin for Clostridium difficile infection: meta-analysis of pivotal randomized controlled trials.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2012Pooled it
- Trial
- A randomised phase 1 study to investigate safety, pharmacokinetics and impact on gut microbiota following single and multiple oral doses in healthy male subjects of SMT19969, a novel agent for Clostridium difficile infections.BMC infectious diseases · 2015Trial
- Treatment of first recurrence of Clostridium difficile infection: fidaxomicin versus vancomycin.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2012Trial
- Fidaxomicin preserves the intestinal microbiome during and after treatment of Clostridium difficile infection (CDI) and reduces both toxin reexpression and recurrence of CDI.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2012Trial
- Reduced acquisition and overgrowth of vancomycin-resistant enterococci and Candida species in patients treated with fidaxomicin versus vancomycin for Clostridium difficile infection.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2012Trial
- Fidaxomicin attains high fecal concentrations with minimal plasma concentrations following oral administration in patients with Clostridium difficile infection.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2012Trial
- Experimental glycopeptide antibiotic EVG7 prevents recurrent Clostridioides difficile infection by sparing members of the Lachnospiraceae family.Nature communications · 2025Article
- Comparative effectiveness of different therapies forThe Lancet regional health. Europe · 2025Article
- European Practice for CDI Treatment.Advances in experimental medicine and biology · 2024Article
- Live biotherapeutic products: a capstone for prevention of recurrentFrontiers in microbiomes · 2024Review
- Omadacycline compared to vancomycin when combined with germinants to disrupt the life cycle ofAntimicrobial agents and chemotherapy · 2023Article
- Real-World Budget Impact of Fidaxomicin versus Vancomycin or Metronidazole for In-Hospital Treatment of Clostridioides difficile InfectionAntibiotics (Basel, Switzerland) · 2023Article
- Fidaxomicin for the Treatment ofAntibiotics (Basel, Switzerland) · 2022Review
- Risk Factors, Diagnosis, and Management ofMicroorganisms · 2022Review
- Article
- The role of oral vancomycin in inducing remission for biologic-experienced ulcerative colitis with concomitant primary sclerosing cholangitis and liver transplantation.Clinical journal of gastroenterology · 2021Article
- Computational modeling of the gut microbiota reveals putative metabolic mechanisms of recurrent Clostridioides difficile infection.PLoS computational biology · 2021Article
- Gut microbiome andTherapeutic advances in gastroenterology · 2021Review
- An Analysis ofOpen forum infectious diseases · 2020Article
23 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
During a 10-day treatment for Clostridium difficile infection, OPT-80 and vancomycin were comparably effective in reducing C. difficile counts. Bacteroides fragilis group counts appeared unaffected with increasing dosages of OPT-80, whereas vancomycin was markedly suppressive. Retention of components of the normal microflora might lower the risk of recurrent disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.